{"entity":{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","aka":[],"tldr":"ESMO is Europe's oncology society, known for its Congress each autumn and the ESMO-MCBS scale for grading the value of new drugs.","summary":"The European Society for Medical Oncology, based in Lugano, is Europe's oncology society, known for its Congress each autumn, the ESMO Breast meeting, the journals Annals of Oncology and ESMO Open, and the ESMO Magnitude of Clinical Benefit Scale that grades the value of new drugs. It issues clinical practice guidelines that OnCo carries as a collection, and its people include Pilar Garrido, Josep Tabernero, Fabrice André, Giuseppe Curigliano and Andrés Cervantes. OnCo links it to bottlenecks on knowledge reaching practice too slowly and the exclusion of older patients, and to ideas such as capping public drug prices to tiers of the ESMO and ASCO value scales. Whether the MCBS can be made to bite on prices is the open question. Its Congress, MCBS and guideline programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.esmo.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["pilar-garrido","andres-cervantes","nathan-cherny","solange-peters"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lugano","country":"CH","lat":46.004,"lng":8.951,"institutionType":"consortium","website":"https://www.esmo.org","programs":["ESMO Congress","ESMO-MCBS","Guidelines"]},"route":"/institutions/esmo/","neighbours":{"person":[{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/"},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/"},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/"},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/"},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/"},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/"},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/"},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/"}],"paper":[{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/"},{"id":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","kind":"paper","name":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/"},{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/"},{"id":"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020","kind":"paper","name":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/"},{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/"},{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/"},{"id":"paper-esmo-rectal-cancer-guideline-ann-oncol-2017","kind":"paper","name":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-rectal-cancer-guideline-ann-oncol-2017/"},{"id":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","kind":"paper","name":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","route":"/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"},{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"collection":[{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/"},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/"}],"bottleneck":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"idea":[{"id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/"},{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/"},{"id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/"},{"id":"idea-tr1-surrogate-validation-programme","kind":"idea","name":"An independent programme that validates surrogate endpoints, setting by setting","route":"/ideas/idea-tr1-surrogate-validation-programme/"},{"id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/"},{"id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/"},{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/"},{"id":"idea-reg-aspirin-pik3ca-implementation","kind":"idea","name":"Get biomarker-directed aspirin after colorectal surgery into labels and guidelines","route":"/ideas/idea-reg-aspirin-pik3ca-implementation/"},{"id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/"},{"id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/"},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/"},{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/"},{"id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/"},{"id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/"},{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/"},{"id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/"},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/"},{"id":"idea-tr1-power-for-meaningful-benefit","kind":"idea","name":"Power trials to detect a benefit patients would value, not the smallest detectable one","route":"/ideas/idea-tr1-power-for-meaningful-benefit/"},{"id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/"},{"id":"idea-cost-indication-based-pricing","kind":"idea","name":"Price a cancer drug by how well it works in each cancer","route":"/ideas/idea-cost-indication-based-pricing/"},{"id":"idea-bio2-cns-cohort-mandate","kind":"idea","name":"Stop excluding brain metastases from cancer trials","route":"/ideas/idea-bio2-cns-cohort-mandate/"},{"id":"idea-cost-value-scale-in-coverage","kind":"idea","name":"Tie coverage and copays to the ESMO benefit scale","route":"/ideas/idea-cost-value-scale-in-coverage/"},{"id":"idea-tr1-win-ratio-net-benefit-endpoint","kind":"idea","name":"Win-ratio endpoints that weigh survival, toxicity and quality of life together","route":"/ideas/idea-tr1-win-ratio-net-benefit-endpoint/"}],"journal":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/"},{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/"}],"institution":[{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","route":"/institutions/champalimaud/"},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/"},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/"},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/"},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/"},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/"},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/"},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/"},{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","route":"/institutions/iscort/"},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/"},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/"},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/"},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/"},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/"}]}}